However, an ICOS antagonist demonstrated a 44% response rate in angioimmunoblastic T‐cell lymphoma; ICOS is highly expressed on T‐follicular helper cells (type of CD4 cell) and proliferation of these cells may be a pathogenic mechanism for these lymphomas. Here, ICOS is linked to lymphoma.